A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
A Local, Multicentre, Open Label Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
2 other identifiers
expanded_access
N/A
0 countries
N/A
Brief Summary
The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 8, 2009
CompletedFirst Posted
Study publicly available on registry
October 9, 2009
CompletedSeptember 27, 2018
September 1, 2018
October 8, 2009
September 25, 2018
Conditions
Keywords
Interventions
Oral dosing twice daily. The dose will depend on the optimized background therapy.
Eligibility Criteria
You may qualify if:
- Subjects who complete the A4001050 study and are continuing to derive benefit from Maraviroc.
- Subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures.
You may not qualify if:
- Subjects who discontinued in A4001050 study.
- Unable to provide consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ViiV Healthcarelead
- Pfizercollaborator
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 8, 2009
First Posted
October 9, 2009
Last Updated
September 27, 2018
Record last verified: 2018-09